0001104659-16-092531.txt : 20160304 0001104659-16-092531.hdr.sgml : 20160304 20160129171907 ACCESSION NUMBER: 0001104659-16-092531 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Animal Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 201 MISSION STREET, SUITE 2375 CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: 415-896-5081 MAIL ADDRESS: STREET 1: 201 MISSION STREET, SUITE 2375 CITY: SAN FRANCISCO STATE: CA ZIP: 94105 CORRESP 1 filename1.htm

 

AEGIS CAPITAL CORP.

810 Seventh Avenue, 18th Floor

New York, New York 10019

 

January 29, 2016

 

VIA EDGAR

 

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Attention: Suzanne Hayes, Assistant Director

 

Re: Jaguar Animal Health, Inc. — Request for Acceleration

Registration Statement on Form S-1

File No. 333-208905

 

Dear Ms. Hayes:

 

Acting on behalf of the several underwriters, we hereby join in the request of Jaguar Animal Health, Inc. that the effective date of the above-captioned Registration Statement be accelerated so that it will become effective at 5:00 p.m., Eastern Time, on February 2, 2016, or as soon thereafter as practicable.

 

Pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, we, acting on behalf of the several underwriters, wish to advise you that, between January 7, 2016 and February 2, 2016, we distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated January 7, 2016 and the Preliminary Prospectus dated January 26, 2016 as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

 

We confirm that we are aware of our obligations under the Securities Act of 1933, as amended, and that we have and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, with respect to the distribution of Prospectuses.  We have been informed by the other underwriters and dealers participating in the distribution of this offering that such persons have and will comply with Rule 15c2-8 with respect to the distribution of Prospectuses.

 

 

Very Truly Yours,

 

 

 

By:  AEGIS CAPITAL CORPORATION

 

 

 

By:

/s/ Nils A. Ericson

 

 

Name: Nils A. Ericson 

 

 

Title: Chief Compliance Officer